IDRA   $7.1774  -1.47% Market Closed

Idera Pharmaceuticals Inc
Last Events:

2023-03-29 Trend pattern changed from нисходящий клин to расходящийся треугольник.

2023-03-29 Signal in Stochastic changed from bullish to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-03-29 Signal in MACD changed from bullish to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.

2023-03-29 Signal in RSI changed from bullish weakening to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-03-29 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-03-29 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-03-29 Trend Power changed from to strong.

2023-03-29 Trend changed from linear up to down and flat.


Current temperature: 1.72
ST: 0, Cor:

Analyst Recommendations:
Number of estimates
Target Price Mean
Mean unverified/preliminary /
Target Price Low / High /
Median / STD DEV /
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi ActivelyBuy Sell -
macd Sell Sell Sell
stoch Sell Sell Sell
ma20 - - -
ma50 - - -
ma100 - - -
Candlestick PatternDec. 28, 2022 Bullish Engulfing - is characterized by a large white body engulfing a preceding smaller black body, which appears during a downtrend. Considered to be a bullish reversal pattern.
ISIN US45168K4058
ceo Mr. John Taylor
Website https://www.iderapharma.com
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.